BELLUS Health and Integris Pharma Ltd. enter into exclusive license agreement for VIVIMIND™ in Greece and Cyprus
LAVAL, QC and ATHENS, Greece, Dec. 1, 2011 /CNW Telbec/ - BELLUS Health Inc. (TSX: BLU) ("BELLUS Health") announced today that it has signed an exclusive license and distribution agreement (the "Agreement") with Integris Pharma Ltd., a wholly owned subsidiary of Coronis Research S.A., a leading independent Clinical Research Organization in Greece. Pursuant to the Agreement, Integris has secured the exclusive right to market and sell VIVIMIND™ in Greece and Cyprus. VIVIMIND™ is a patented natural health product that has been shown to help support the specific area of the brain known as the hippocampus, the region responsible for memory and learning. Financial terms of this agreement were not disclosed.
Integris Pharma Ltd. intends to immediately proceed with filing for regulatory approval and expects to launch VIVIMIND™ in Greece and Cyprus in the second quarter of 2012.
"Integris puts the utmost importance on products that meet the highest levels quality, safety and efficacy and VIVIMIND™ fits perfectly within those criteria" said Dr. Harry Therianos MD, PhD, Managing Director of Integris Pharma Ltd. "Given the strong clinical data generated from two phase III clinical trials conducted in over 2,000 patients and considering the completeness of the VIVIMIND™ regulatory dossier which includes approvals in Canada, Italy and Spain, we expect to receive formal regulatory approval from the Greek authorities in the first quarter of 2012. We look forward to making this innovative product for cognition available to consumers throughout Greece and Cyprus." concluded Dr. Therianos.
"This transaction fits within our strategy of forming partnerships with strong regional industry players to build a worldwide distribution network for VIVIMIND™. With its in-depth understanding of this region, Integris Pharma is the right partner to realize VIVIMIND's™ commercial potential in Greece and Cyprus" said Mr. Roberto Bellini, President and Chief Executive Officer of BELLUS Health.
VIVIMIND™ is scientifically proven to help support the specific area of the brain known as the hippocampus, a region responsible for memory and learning. The active ingredient behind VIVIMIND™, homotaurine, is a naturally occurring amino acid with unique properties found in certain seaweeds. VIVIMIND™ is intended to be used by normal aging adults.
VIVIMIND™ was subject to more than 15 years of significant scientific research, including clinical testing in over 2,000 people at European, American and Canadian medical centres. In a large, controlled clinical study, VIVIMIND™ was shown to reduce by 68% the hippocampus volume loss in Alzheimer's disease patients over 18 months.1
Regulatory approvals for the commercial sale of VIVIMIND™ were obtained in Italy and in Spain in 2009, and a Natural Health Product Number was issued by Health Canada for VIVIMIND™ in September 2010.
1 Gauthier S. et al, Journal Nutrition Health Aging, 2009; 13 (6): 550-7
About Integris Pharma Ltd.
Integris Pharma Ltd. is a specialty pharmaceutical company operating exclusively in the CNS area. Integris representatives detail more than 1,000 psychiatrists & neurologists, all over Greece.
About CORONIS Research SA
CORONIS Research SA is a leading Clinical Research Organization (CRO) with broad expertise in every phase of the drug development and clinical research continuum, delivering a full spectrum of services to national and international pharmaceutical, biotechnology and medical device industries and other healthcare-related organisations.
About BELLUS Health
BELLUS Health is a development-focused health company concentrating on the development of products that provide innovative health solutions and address critical unmet medical needs. For further information on BELLUS Health, please visit www.bellushealth.com .
Forward Looking Statements
Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond BELLUS Health Inc.'s control. Such risks include but are not limited to: the ability to obtain financing immediately in current markets, the impact of general economic conditions, general conditions in the pharmaceutical and/or nutraceutical industry, changes in the regulatory environment in the jurisdictions in which the BELLUS Health Group does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation, achievement of forecasted burn rate, and that actual results may vary once the final and quality-controlled verification of data and analyses has been completed. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. The reader should not place undue reliance, if any, on any forward-looking statements included in this news release. These statements speak only as of the date made and BELLUS Health Inc. is under no obligation and disavows any intention to update or revise such statements as a result of any event, circumstances or otherwise, unless required by applicable legislation or regulation. Please see the Company's public fillings including the Annual Information Form of BELLUS Health Inc. for further risk factors that might affect the BELLUS Health Group and its business
NATIONAL Public Relations